Hackensack biotech company gets Israeli patent for therapy

* BrainStorm develops cell treatments for neurodegenerative diseases

BrainStorm Cell Therapeutics Inc., a biotechnology company in Hackensack, said Monday that it has received patent approval in Israel for its NurOwn technology.

NurOwn is self-transplanting adult stem-cell therapy.

BrainStorm said it received a notice of allowance from Israel's Patent Office for the rights to methods of producing neurotrophic, factor-secreting cells derived from mesenchymal stem cells and methods of using those cells for the treatment of neurologic diseases. The patent is held jointly with Tel Aviv University's technology transfer company, Ramot.

"This patent allowance in Israel further extends the geographic reach of our intellectual property, as we already have received similar claims in the U.S., with additional filings pending elsewhere," said BrainStorm's chief executive officer, Tony Fiorino, in a statement.

BrainStorm develops adult cell therapies from bone marrow cells to treat neurodegenerative diseases.

The business also has operations in Israel.

Email: anzidei@northjersey.com

See the original post here:
Hackensack biotech company gets Israeli patent for therapy